TriaGen Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-12,411
Closed -$1.05M 178
2021
Q2
$1.05M Buy
12,411
+39
+0.3% +$3.32K 0.54% 65
2021
Q1
$1.1M Buy
12,372
+3,345
+37% +$332K 0.63% 56
2020
Q4
$842K Buy
+9,027
New +$719K 0.49% 69

Other funds holding ARKG

TriaGen Wealth Management's ARKG Position: Q3 2021 in Review

TriaGen Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 12,411 shares — an estimated $1.05M sold.

TriaGen Wealth Management first reported a position in ARKG in Q4 2020 and held it in 3 quarters. The position peaked at $1.1M in Q1 2021. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

  • TriaGen Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
  • TriaGen Wealth Management sold 12,411 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $1.05M.
  • TriaGen Wealth Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 3 quarters.
  • TriaGen Wealth Management's ARK Genomic Revolution ETF position peaked at $1.1M in Q1 2021.
  • 468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on TriaGen Wealth Management's 13F filing for Q3 2021, filed 10 Nov 2021.